JP2025020148A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2025020148A5 JP2025020148A5 JP2024179270A JP2024179270A JP2025020148A5 JP 2025020148 A5 JP2025020148 A5 JP 2025020148A5 JP 2024179270 A JP2024179270 A JP 2024179270A JP 2024179270 A JP2024179270 A JP 2024179270A JP 2025020148 A5 JP2025020148 A5 JP 2025020148A5
- Authority
- JP
- Japan
- Prior art keywords
- receptor antagonist
- crf
- molecular weight
- use according
- low molecular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762545406P | 2017-08-14 | 2017-08-14 | |
| US62/545,406 | 2017-08-14 | ||
| JP2019572817A JP7398963B2 (ja) | 2017-08-14 | 2018-08-14 | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 |
| PCT/US2018/046760 WO2019036503A1 (en) | 2017-08-14 | 2018-08-14 | CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS |
| JP2023146415A JP7573080B2 (ja) | 2017-08-14 | 2023-09-08 | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023146415A Division JP7573080B2 (ja) | 2017-08-14 | 2023-09-08 | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025020148A JP2025020148A (ja) | 2025-02-12 |
| JP2025020148A5 true JP2025020148A5 (enExample) | 2025-03-05 |
Family
ID=65362494
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572817A Active JP7398963B2 (ja) | 2017-08-14 | 2018-08-14 | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 |
| JP2023146415A Active JP7573080B2 (ja) | 2017-08-14 | 2023-09-08 | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 |
| JP2024179270A Pending JP2025020148A (ja) | 2017-08-14 | 2024-10-11 | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572817A Active JP7398963B2 (ja) | 2017-08-14 | 2018-08-14 | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 |
| JP2023146415A Active JP7573080B2 (ja) | 2017-08-14 | 2023-09-08 | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 |
Country Status (11)
| Country | Link |
|---|---|
| US (9) | US20210361664A1 (enExample) |
| EP (1) | EP3628005A4 (enExample) |
| JP (3) | JP7398963B2 (enExample) |
| KR (2) | KR20250022913A (enExample) |
| CN (2) | CN110996943A (enExample) |
| AU (2) | AU2018317398A1 (enExample) |
| BR (1) | BR112020002967A2 (enExample) |
| CA (1) | CA3064464A1 (enExample) |
| EA (1) | EA202090450A1 (enExample) |
| MX (2) | MX2019015320A (enExample) |
| WO (1) | WO2019036503A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3096756T3 (fi) | 2014-01-21 | 2024-08-14 | Neurocrine Biosciences Inc | Crf1-reseptorin antagonisteja synnynnäisen lisämunuaisen liikakasvun hoitoon |
| KR20250022913A (ko) | 2017-08-14 | 2025-02-17 | 스프루스 바이오사이언시스 인코포레이티드 | 코티코트로핀 방출 인자 수용체 길항제 |
| EP4438124A3 (en) * | 2018-04-27 | 2024-12-18 | Spruce Biosciences, Inc. | Methods for treating testicular and ovarian adrenal rest tumors |
| TW202446384A (zh) | 2018-12-07 | 2024-12-01 | 美商紐羅克里生物科學有限公司 | 用於治療先天性腎上腺增生之crf1受體拮抗劑、醫藥配方及其固體形式 |
| CA3147891A1 (en) * | 2019-07-19 | 2021-01-28 | Spruce Biosciences, Inc. | Methods of treating congenital adrenal hyperplasia |
| WO2021062246A1 (en) | 2019-09-27 | 2021-04-01 | Neurocrine Biosciences, Inc. | Crf receptor antagonists and methods of use |
| AU2021324839B2 (en) * | 2020-08-12 | 2024-02-29 | Spruce Biosciences, Inc. | Methods and compositions for treating polycystic ovary syndrome |
| EP4203964A1 (en) * | 2020-08-26 | 2023-07-05 | Neurocrine Biosciences, Inc. | Crf receptor antagonists and methods of use |
| US11708372B2 (en) | 2021-11-19 | 2023-07-25 | Spruce Biosciences, Inc. | Crystalline composition of tildacerfont and methods of use and preparation thereof |
| WO2025188842A1 (en) * | 2024-03-08 | 2025-09-12 | Spruce Biosciences, Inc. | Amorphous solid dispersion of tildacerfont formulations |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0173172B1 (ko) | 1992-12-17 | 1999-02-01 | 알렌 제이. 스피겔 | Crf 길항제로서의 피롤로피리미딘 |
| ATE336495T1 (de) | 1996-02-07 | 2006-09-15 | Neurocrine Biosciences Inc | Pyrazolopyrimidine als crf rezeptor-antagonisten |
| EA006626B1 (ru) | 1996-07-24 | 2006-02-24 | Дюпон Фармасьютикалз Компани | Азолопиримидины, фармацевтическая композиция и способ лечения |
| JP4704521B2 (ja) | 1996-07-24 | 2011-06-15 | ブリストル−マイヤーズ スクイブ ファーマ カンパニー | アゾロトリアジン類およびアゾロピリミジン類 |
| NZ333302A (en) | 1996-08-28 | 2000-08-25 | Pfizer | Substituted 6,5-hetero-bicyclic derivatives for the prevention or inhibition of a disorder that can be treated by antagonising corticotropin releasing factor |
| CA2614603C (en) | 1998-01-28 | 2011-08-16 | Bristol-Myers Squibb Pharma Company | Azolo triazines and pyrimidines |
| IL137019A (en) | 1998-01-28 | 2010-11-30 | Du Pont Pharm Co | 2,7 - dimethyl - 4 - (substituted amino) - 8 - arylpyrazolo [1,5-a] triazine derivatives and pharmaceutical compositions containing them |
| EP1040831A3 (en) | 1999-04-02 | 2003-05-02 | Pfizer Products Inc. | Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death |
| WO2000059908A2 (en) | 1999-04-06 | 2000-10-12 | Du Pont Pharmaceuticals Company | Pyrazolopyrimidines as crf antagonists |
| CZ20021089A3 (cs) | 1999-09-30 | 2002-11-13 | Neurogen Corporation | Aminosustituované pyrazolo[1,5-a]-1,5-pyrimidiny a pyrazolo[1,5-a]-1,3,5-triaziny |
| BR0008059A (pt) | 1999-12-08 | 2002-03-26 | Pharmacia Corp | Composições de valdecoxib |
| DE60218434T2 (de) | 2001-03-13 | 2007-11-08 | Bristol-Myers Squibb Pharma Co. | 4-(2-BUTYLAMINO)-2,7-DIMETHYL-8-(2-METHYL-6-METHOXYPYRID-3-YL) PYRAZOLO- 1,5-Aö-1,3,5-TRIAZIN, SEINE ENANTIOMEREN UND PHARMAZEUTISCH ANNEHMBARE SALZE ALS CORTICOTROPIN-RELEASING-FACTOR-REZEPTOR-LIGANDEN |
| US20050085479A1 (en) | 2003-08-27 | 2005-04-21 | Pharmacia Corporation | Mediated central nervous system compositions of a cyclooxygenase-2 selective inhibitor and a corticotropin releasing factor antagonist for the treatment of ischemic disorders or injury |
| WO2005053796A1 (en) | 2003-12-02 | 2005-06-16 | B & B Beheer Nv | Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists |
| RU2394035C2 (ru) | 2003-12-22 | 2010-07-10 | Эс Би ФАРМКО ПУЭРТО РИКО ИНК. | Антагонисты crf-рецепторов и способы, относящиеся к ним |
| US20070129382A1 (en) | 2004-02-13 | 2007-06-07 | Dimitri Grigoriadis | Crf receptor antagonists, their preparations, their pharmaceutical composition, and their uses |
| BRPI0507609A (pt) | 2004-02-13 | 2007-07-03 | Pfizer Prod Inc | combinações terapêuticas de anti-psicóticos atìpicos com antagonistas de fator de liberação de corticotropina |
| EP1781257B1 (en) * | 2004-08-13 | 2018-12-19 | Emisphere Technologies, Inc. | Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent |
| PT1869049E (pt) | 2005-03-21 | 2009-05-26 | Lilly Co Eli | Compostos de imidazopiridazina |
| CN101516835A (zh) | 2006-07-19 | 2009-08-26 | 俄亥俄州立大学研究基金会 | 选择性雄激素受体调节剂、它们的类似物和衍生物以及它们的用途 |
| ES2350282T3 (es) | 2006-09-20 | 2011-01-20 | Eli Lilly And Company | Tiazol pirazolopirimidinas como antagonistas del receptor de crf1. |
| KR101088196B1 (ko) | 2006-09-20 | 2011-11-30 | 일라이 릴리 앤드 캄파니 | 티오펜 피라졸로피리미딘 화합물 |
| US8952207B2 (en) | 2007-09-11 | 2015-02-10 | The University Of Houston System | Copper-catalyzed C—H bond arylation |
| US8318813B2 (en) | 2007-09-13 | 2012-11-27 | Lcs Group, Llc | Method of treating binge eating disorder |
| WO2010039678A1 (en) | 2008-10-02 | 2010-04-08 | Eli Lilly And Company | Thiazolyl-pyrazolopyrimidine compounds as synthetic intermediates and related synthetic processes |
| US8153962B2 (en) * | 2008-12-24 | 2012-04-10 | Quest Diagnostics Investments Incorporated | Mass spectrometry assay for congenital adrenal hyperplasia |
| PT2519230T (pt) * | 2009-12-31 | 2019-01-18 | Marius Pharmaceuticals Llc | Modulação de solubilidade, estabilidade, absorção, metabolismo e perfil farmacocinético de fármacos lipofílicos por esteróis |
| US9750568B2 (en) | 2012-03-08 | 2017-09-05 | Medtronic Ardian Luxembourg S.A.R.L. | Ovarian neuromodulation and associated systems and methods |
| US20150094310A1 (en) | 2012-04-23 | 2015-04-02 | Holsboermaschmeyer Neurochemie Gmbh | Crhr1 antagonists for use in the treatment of patients having crh overactivity |
| FI3096756T3 (fi) * | 2014-01-21 | 2024-08-14 | Neurocrine Biosciences Inc | Crf1-reseptorin antagonisteja synnynnäisen lisämunuaisen liikakasvun hoitoon |
| EP3277191B1 (en) | 2015-03-31 | 2023-11-15 | May Health US Inc. | Methods and systems for the manipulation of ovarian tissues |
| AU2018318990B2 (en) | 2017-08-14 | 2023-01-05 | Spruce Biosciences, Inc. | Corticotropin releasing factor receptor antagonists |
| KR20250022913A (ko) | 2017-08-14 | 2025-02-17 | 스프루스 바이오사이언시스 인코포레이티드 | 코티코트로핀 방출 인자 수용체 길항제 |
| EP4438124A3 (en) | 2018-04-27 | 2024-12-18 | Spruce Biosciences, Inc. | Methods for treating testicular and ovarian adrenal rest tumors |
| TW202446384A (zh) | 2018-12-07 | 2024-12-01 | 美商紐羅克里生物科學有限公司 | 用於治療先天性腎上腺增生之crf1受體拮抗劑、醫藥配方及其固體形式 |
| US20200255436A1 (en) | 2019-02-12 | 2020-08-13 | Spruce Biosciences, Inc. | Corticotropin releasing factor receptor antagonists |
| CA3147891A1 (en) | 2019-07-19 | 2021-01-28 | Spruce Biosciences, Inc. | Methods of treating congenital adrenal hyperplasia |
| AU2021324839B2 (en) | 2020-08-12 | 2024-02-29 | Spruce Biosciences, Inc. | Methods and compositions for treating polycystic ovary syndrome |
| US11708372B2 (en) | 2021-11-19 | 2023-07-25 | Spruce Biosciences, Inc. | Crystalline composition of tildacerfont and methods of use and preparation thereof |
| WO2023091684A1 (en) | 2021-11-19 | 2023-05-25 | Spruce Biosciences, Inc. | Crystalline composition of tildacerfont and methods of use and preparation thereof |
-
2018
- 2018-08-14 KR KR1020257004457A patent/KR20250022913A/ko active Pending
- 2018-08-14 CA CA3064464A patent/CA3064464A1/en active Pending
- 2018-08-14 WO PCT/US2018/046760 patent/WO2019036503A1/en not_active Ceased
- 2018-08-14 AU AU2018317398A patent/AU2018317398A1/en not_active Abandoned
- 2018-08-14 US US16/639,541 patent/US20210361664A1/en not_active Abandoned
- 2018-08-14 EP EP18846689.0A patent/EP3628005A4/en active Pending
- 2018-08-14 EA EA202090450A patent/EA202090450A1/ru unknown
- 2018-08-14 MX MX2019015320A patent/MX2019015320A/es unknown
- 2018-08-14 CN CN201880038569.3A patent/CN110996943A/zh active Pending
- 2018-08-14 BR BR112020002967-0A patent/BR112020002967A2/pt not_active Application Discontinuation
- 2018-08-14 JP JP2019572817A patent/JP7398963B2/ja active Active
- 2018-08-14 KR KR1020207004095A patent/KR20200040761A/ko not_active Ceased
- 2018-08-14 CN CN202410709847.0A patent/CN118845788A/zh active Pending
-
2019
- 2019-04-18 US US16/388,620 patent/US10849908B2/en active Active
- 2019-12-16 MX MX2023000501A patent/MX2023000501A/es unknown
-
2020
- 2020-10-05 US US17/063,592 patent/US11344557B2/en active Active
- 2020-10-22 US US17/078,054 patent/US11007201B2/en active Active
-
2021
- 2021-06-25 US US17/359,411 patent/US11351177B2/en active Active
- 2021-06-25 US US17/359,414 patent/US11311549B2/en active Active
-
2022
- 2022-01-27 US US17/586,228 patent/US20220143037A1/en not_active Abandoned
- 2022-12-09 US US18/078,649 patent/US20230321112A1/en active Pending
-
2023
- 2023-01-13 AU AU2023200189A patent/AU2023200189B2/en active Active
- 2023-04-26 US US18/307,718 patent/US12115166B2/en active Active
- 2023-09-08 JP JP2023146415A patent/JP7573080B2/ja active Active
-
2024
- 2024-10-11 JP JP2024179270A patent/JP2025020148A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025020148A5 (enExample) | ||
| Sitruk-Ware | New progestagens for contraceptive use | |
| Genazzani et al. | Long-term low-dose dehydroepiandrosterone oral supplementation in early and late postmenopausal women modulates endocrine parameters and synthesis of neuroactive steroids | |
| JP2656958B2 (ja) | ホルモン依存性腫瘍治療剤 | |
| Sitruk-Ware et al. | Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills | |
| CN102811730B (zh) | 孕激素作为糖皮质激素增敏剂的使用 | |
| Sitruk-Ware et al. | The use of newer progestins for contraception | |
| Sitruk-Ware | Pharmacology of different progestogens: the special case of drospirenone | |
| Africander et al. | Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception | |
| Schindler et al. | Reprint of classification and pharmacology of progestins | |
| Krattenmacher | Drospirenone: pharmacology and pharmacokinetics of a unique progestogen | |
| Fruzzetti et al. | Review of clinical experience with estradiol in combined oral contraceptives | |
| Schindler | The “newer” progestogens and postmenopausal hormone therapy (HRT) | |
| JP2013518908A5 (enExample) | ||
| IL286048B2 (en) | Abiraterone decanoate and its pharmaceutical salts, pharmaceutical preparations containing them, their uses and preparation | |
| CA2326654A1 (en) | Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways | |
| Requena et al. | Oral contraceptives in dermatology | |
| Voutsadaki et al. | Hypogonadism in adolescent girls: treatment and long-term effects | |
| JPWO2021016208A5 (enExample) | ||
| Fedotcheva et al. | Dehydroepiandrosterone and Its Metabolite 5-Androstenediol: New Therapeutic Targets and Possibilities for Clinical Application | |
| JP2008534533A5 (enExample) | ||
| CN106232107A (zh) | 用于抗孕激素的阴道递送的制剂和方法 | |
| Thomas et al. | Medroxyprogesterone acetate binds the glucocorticoid receptor to stimulate α-ENaC and sgk1 expression in renal collecting duct epithelia | |
| JP6343619B2 (ja) | プロゲステロン依存性病態を処置する方法およびその組成物 | |
| Schane et al. | ORAL PROGESTATIONAL ACTIVITY OF SPIRONOLACTONE1 |